DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07207148

Recruiting

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

100

estimated

Study population

Multiple sclerosis, Obesity / overweight

Key I/E criterion

•BMI ≥24

Primary endpoint

•PIRA

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07207148
Org study IDSTU00224018

Timeline

Milestones

Study first posted2025-10-03actual
Study start2025-11-15actual
Last update posted2026-03-17actual
Primary completion2028-04-01estimated
Study completion2028-08-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Multiple sclerosisObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Individuals with multiple sclerosis already treated with both Ocrelizumab and are either currently on a GLP-1 agonist or who are soon starting a GLP-1 agonist.

Inclusion criteria

•Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,
•Adult age 18-70 years,
•BMI >=24.0 kg/m2,
•Taken at least one dose of Ocrelizumab prior to study entry,
•EDSS <7.0,
•Able to provide individual informed consent,
•MRI available to confirm the diagnosis of MS.

Exclusion criteria

•Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
•Current clinical trial participant,
•Unable to speak a language for which translation can be found in the hospital system,
•Unclear documentation of MS diagnosis or prior or current MS treatment,
•Relapse within the past 3 months,
•Recent major surgical procedure in the past 6 months,
•Exposure to steroids (systemic) within the past 3 months,
•Not on Ocrelizumab in the past >9 months,
•Moribund status,
•Underweight or experiencing protein malnutrition,
•Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, dementia, etc.),
•Unable to complete the study activities for any reason as deemed by the study investigator.

Additional Inclusion Criteria Aim 1:

•Exposed to GLP-1 agonist treatment in the last 3 years or less, or starting on a GLP-1 agonist in the coming <3 months,
•Willing to report monthly patient-reported outcomes remotely or in-person.

Additional Inclusion Criteria Aim 2:

•Able to present for baseline and follow up in person,
•Unexposed to a GLP-1 agonist in the past year,
•Starting on a GLP-1 agonist in the next <6 months,
•Plan to be exposed to GLP-1 agonist for a minimum of 72 weeks following enrollment.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
1
Other (unclassified)
1

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

PIRA

Time frame:From enrollment to the end of study at 72 weeks.

categorical status, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Neurofilament light chain

Time frame:From the start of Aim 2 to the end of treatment at 72 weeks.

concentration, descriptive

Publications (14)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.